Bradley Tait

This inventor holds 19 USPTO granted patents and 16 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Proteostasis Regulation. Top assignees: Proteostasis Therapeutics, Inc., Frequency Therapeutics, Inc., Kineta, Inc.. Active years: 2016-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bradley Tait. Retrieved from https://idiyas.com/inventor/bradley-tait

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 16)

% Patents Active = 89.5

CIPO Patents = 2 (Patent Applications = 10)

EPO Patents = 4 (Patent Applications = 11)

Average Co-Inventor Count = 3.4

ph-index = 6

Forward Citations = 77(Granted Patents)

Location History:

Malden, MA (US) (2016 - 2021)
North Andover, MA (US) (2021 - 2024)

Company Filing History:

15 out of 24

Proteostasis Therapeutics, Inc.

patents

2 out of 14

Frequency Therapeutics, Inc.

Years Active: 2016-2024

Loading Chart...

Areas of Expertise:

Proteostasis Regulators

CFTR Activity

Proteasome Compounds

Cystic Fibrosis

1H-Pyrrole-2,5-Dione

5-Heteroarylpyrazol

3-Heteroarylisoxazol

Dihydro-2H-Pyrrol

5-Phenylthiazol

Compositions

Derivatives

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12180189 - Proteostasis regulators (2024-12-31),

2. 11958873 - Proteasome activity enhancing compounds (2024-04-16),

3. 11746098 - Proteasome activity enhancing compounds (2023-09-05),

4. 11242361 - Proteasome activity enhancing compounds (2022-02-08),

5. 11098035 - Compounds, compositions, and methods for increasing CFTR activity (2021-08-24),

6. 11066419 - 1H-pyrrole-2,5-dione compounds and methods of using same (2021-07-20),

7. 10738040 - Compounds, compositions, and methods for increasing CFTR activity (2020-08-11),

8. 10738011 - Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis (2020-08-11),

9. 10532996 - Proteostasis regulators (2020-01-14),

10. 10392378 - Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis (2019-08-27),

11. 10392372 - Compounds, compositions, and methods for increasing CFTR activity (2019-08-27),

12. 10383881 - 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same (2019-08-20),

13. 10344023 - Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis (2019-07-09),

14. 10174014 - Compounds, compositions, and methods for increasing CFTR activity (2019-01-08),

15. 10017503 - Compounds, compositions, and methods for increasing CFTR activity (2018-07-10),

Title: The Innovative Journey of Bradley Tait

Introduction

Bradley Tait, based in Malden, Massachusetts, is a prolific inventor with a remarkable portfolio of 19 patents. His work primarily focuses on advancements in proteostasis, which has significant implications for treating various medical conditions.

Latest Patents

Among Bradley Tait's latest contributions are his groundbreaking patents related to proteostasis regulators and proteasome activity enhancing compounds. The proteostasis regulators patent encompasses compounds represented by Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX). These include pharmaceutically acceptable salts, prodrugs, and solvates, aimed at offering therapeutic solutions for conditions linked to proteostasis dysfunction. Similarly, his patents on proteasome activity enhancing compounds detail various compositions and methods intended to address issues arising from proteostasis abnormalities.

Career Highlights

Throughout his career, Bradley Tait has been associated with prominent companies such as Proteostasis Therapeutics, Inc. and Frequency Therapeutics, Inc. His work in these organizations has been pivotal in pushing the boundaries of knowledge and technology related to proteostasis.

Collaborations

Collaboration has played an essential role in Tait's career, allowing him to engage with talented professionals. One notable partnership includes working with Benito Munoz and Cecilia M. Bastos, which has contributed to the success and advancement of his innovative projects.

Conclusion

Bradley Tait's dedication to innovation and invention in the field of proteostasis is evident through his extensive patent portfolio and collaborative efforts. His work not only advances scientific understanding but also holds the potential to significantly improve treatment options for conditions linked to proteostasis dysfunction.

Profile summary based on public USPTO records.